Managing the innovation pipeline

Benoît Gailly
Additional contact information
Benoît Gailly: Université Catholique de Louvain (UCL)

Chapter Chapter 7 in Developing Innovative organizations, 2011, pp 177-195 from Palgrave Macmillan

Abstract: Abstract The development of a new drug based on a new molecule, as discussed in Chapter 6, is probably one of the most complex product development processes, and bringing a new drug to market can cost hundreds of millions of euros and has to go through very tight regulatory steps, controlled by both national and international agencies. Finally, the full process has to be completed quickly enough to allow the drug to come to market well before the initial patents expire. Leading pharmaceutical firms have therefore had to develop, over time, the capability of managing product development costs, discipline and speed in an effective way.

Keywords: Project Portfolio; Innovation Opportunity; Sunk Cost Fallacy; Decision Meeting; Project Champion (search for similar items in EconPapers)
Date: 2011
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:pal:palchp:978-0-230-29528-5_7

Ordering information: This item can be ordered from
http://www.palgrave.com/9780230295285

DOI: 10.1057/9780230295285_7

Access Statistics for this chapter

More chapters in Palgrave Macmillan Books from Palgrave Macmillan
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().